Novo Nordisk Wegovy Eyes New U.S. Sales Channel Through Telehealth Partnership

NEW YORK, November 3, 2025 – Novo Nordisk’s (NVO) weight-loss drug Wegovy could gain a new U.S. distribution channel through telehealth company Hims & Hers, which said it is in “active discussions” with the Danish drugmaker ¹. The potential partnership comes as Novo faces slowing Wegovy sales growth amid increased competition from compounded versions of its obesity medications.

Hims & Hers in “active discussions” with Novo Nordisk
New distribution channel could expand Wegovy U.S. access
Comes amid slowing growth for obesity drug sales

Market Context

The discussions represent Novo’s latest effort to broaden access to Wegovy as the company grapples with supply constraints and competitive pressures. In July, Novo slashed its Wegovy sales forecast to no more than 14% growth this year, citing impact from compounded versions of its drugs ⁸.

Novo recently entered a partnership with retail giant Costco to promote awareness and sales of its diabetes and obesity medications ⁷. The company’s top investor has also seized board control amid efforts to revive sales in the competitive U.S. weight-loss drug market ⁶.

Telehealth Distribution Strategy

A partnership with Hims & Hers would tap into the growing telehealth market for weight-loss treatments. The San Francisco-based company specializes in direct-to-consumer healthcare services and could provide Novo with an additional avenue to reach patients seeking obesity treatment.

Telehealth platforms have become increasingly popular distribution channels for GLP-1 medications like Wegovy, offering patients convenient access to prescriptions and ongoing medical supervision. The model could help Novo compete more effectively against compounded versions of semaglutide that have captured market share.

Competitive Landscape

Novo faces intensifying competition in the obesity drug market from both traditional pharmaceutical rivals and compounding pharmacies. The company’s blockbuster drugs Ozempic and Wegovy have driven significant revenue growth, but demand growth has begun to slow as the market matures ⁵.

Rival Pfizer is also working to establish its position in the obesity treatment space, creating additional competitive pressure for Novo’s market-leading position ⁹. The Danish company will present new Wegovy data at the upcoming American Association for the Study of Liver Diseases annual meeting, potentially showcasing additional therapeutic benefits ².

Financial Implications

Any expansion of Wegovy’s distribution network could provide a boost to Novo’s sales trajectory at a critical time. The company’s third-quarter results are expected to hinge heavily on performance of its Ozempic and Wegovy franchises as growth moderates from previous highs.

While specific terms of potential partnership discussions with Hims & Hers have not been disclosed, the collaboration could represent a strategic shift toward direct-to-consumer healthcare delivery models that have gained traction during the post-pandemic era.

Not investment advice. For informational purposes only.